Join the CRISPR revolutionReason to invest in NASDAQ:NTLA and NASDAQ:BEAM
Groundbreaking CRISPR Tech.
Promising Treatment Pipeline.
Big Pharma Partnerships.
Positioned to make a significant difference in healthcare.
−5.42USD
−481.19 MUSD
36.28 MUSD
93.89 M
About Intellia Therapeutics, Inc.
Sector
Industry
CEO
John M. Leonard
Website
Headquarters
Cambridge
Employees (FY)
526
Founded
2014
ISIN
US45826J1051
FIGI
BBG007KC7PB0
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
NTLA shortThis is only my second published idea and my last published trade was successful so with 100% accuracy the probability that this is going to pan out the way I want is infintesimal.
Here goes anyways. This is at what I would consider a key level of resistance permitting for a tight stop loss but de
Biotechs Are Dangerous, But NTLA has Little resistance Over 55Many biotechs are trying to "turn the corner". Over 55 and NTLA could much higher. I am going to look at bullish call spread ideas this week.
NTLA Intellia Therapeutics Inc. BPC Chart Overview 03/28/22Intellia Therapeutics Inc. NASDAQ: NTLA
Chart Overview 03/28/22
Intellia is trading in a 9-month downward channel pullback, closing the gap created by the release of Phase 1 data of NTLA-2001 to treat ATTR. The release caused a bull pennant that led to a reversal into a downward channel. We are tr
Intellia devolving. NTLAGoals 61, 53. Invalidation at 110.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fra
$NTLA back into the channelWe lost 89.95 so looks like we're gonna be bouncing around the channel again. Bottom of the channel is 51.11 so it may wanna wait before playing calls.
NTLA : SWING TRADEIntellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Summary :
Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology.
Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 9
12/19/21 NTLAIntellia Therapeutics, Inc. ( NASDAQ:NTLA )
Sector: Health Technology (Biotechnology)
Market Capitalization: 9.545B
Current Price: $128.23
Breakout price: $125.25 (hold above)
Buy Zone (Top/Bottom Range): $118.80-$110.25
Price Target: $170.00-$174.00
Estimated Duration to Target: 84-90d
Contract
NTLANot the best option possible, but the rebound that occurred is interesting. We "held" the trend during the week, as well as 50%, formally a large hidden . There may be an increase in the fact of holding the blue level.
11/ 05 /21 Oppenheimer Supports Performance 145,0
11/ 05 /21 HC Wainwright & Co.
NLTA: Should be heading to retest recent high of $200Healthcare sector seems bullish overall. Lots of stocks within this sector have bullish bias as well.
NTLA have a pretty well defined ABCDE Triangle pattern, and any time now is a good time to enter.
Stop loss below the low of C i.e. around $140.
Disclaimer: I'm not giving any trading and investi
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where NTLA is featured.
Frequently Asked Questions
The current price of NTLA is 21.50 USD — it has decreased by 1.42% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Intellia Therapeutics, Inc. stocks are traded under the ticker NTLA.
Intellia Therapeutics, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
NTLA stock is 3.20% volatile and has beta coefficient of 2.78. Check out the list of the most volatile stocks — is Intellia Therapeutics, Inc. there?
One year price forecast for Intellia Therapeutics, Inc. has a max estimate of 144.00 USD and a min estimate of 24.00 USD.
NTLA earnings for the last quarter are −1.38 USD whereas the estimation was −1.50 USD which accounts for 7.91% surprise. Estimated earnings for the next quarter are −1.44 USD. See more details about Intellia Therapeutics, Inc. earnings.
Intellia Therapeutics, Inc. revenue for the last quarter amounts to 11.99 M USD despite the estimated figure of 13.05 M USD. In the next quarter revenue is expected to reach 12.74 M USD.
Yes, you can track Intellia Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
NTLA stock has fallen by 13.17% compared to the previous week, the month change is a 23.35% fall, over the last year Intellia Therapeutics, Inc. has showed a 45.14% decrease.
NTLA net income for the last quarter is −132.16 M USD, while the quarter before that showed −122.22 M USD of net income which accounts for −8.13% change. Track more Intellia Therapeutics, Inc. financial stats to get the full picture.
Today Intellia Therapeutics, Inc. has the market capitalization of 2.07 B, it has increased by 0.80% over the last week.
No, NTLA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NTLA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Intellia Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 526.00 employees. See our rating of the largest employees — is Intellia Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Intellia Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Intellia Therapeutics, Inc. stock shows the strong sell signal. See more of Intellia Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Intellia Therapeutics, Inc. future price: according to them, NTLA price has a max estimate of 144.00 USD and a min estimate of 24.00 USD. Read a more detailed Intellia Therapeutics, Inc. forecast: see what analysts think of Intellia Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Intellia Therapeutics, Inc. EBITDA is −506.32 M USD, and current EBITDA margin is −1.40 K%. See more stats in Intellia Therapeutics, Inc. financial statements.